Evidence Grade C — Moderate human evidence. 170 published studies, 28 human. 0 registered clinical trials.
Medically reviewed by a licensed medical professional
Pentadecapeptide BPC is an older name for the same compound known as BPC-157. The evidence base, regulatory status, and limitations are identical. See the BPC-157 entry for the full assessment.
Pentadecapeptide BPC is also known by these brand and alternate names:
170 published studies: 28 human, 91 animal, 17 in-vitro, 29 reviews
This entry reflects historical nomenclature for the compound more commonly known as BPC-157. The evidence base, regulatory status, and limitations described for BPC-157 (#81) apply identically to this compound. See compound #81 for the full assessment.
No marketing authorisation. No human Phase III trials. No established human dosing or safety profile.
Identical to BPC-157 (#81). Research in animal models has proposed multiple mechanisms. No mechanisms have been validated in controlled human trials.
This compound is identical to BPC-157. All information in the BPC-157 entry applies here. In brief: over 100 animal studies (predominantly from a single research group at the University of Zagreb) show positive results for tissue repair, but there are no completed human Phase III trials, no established human dosing or safety profile, and products from unregulated sources lack pharmaceutical quality assurance.
PeptideTrace tracks 0 registered clinical trials for Pentadecapeptide BPC sourced from ClinicalTrials.gov.
No trials registered on ClinicalTrials.gov for this compound.
Pentadecapeptide BPC is the parent compound designation for BPC-157: same 15-amino-acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, MW 1,419.53 Da) from human gastric juice protein. Earlier nomenclature before BPC-157 became standard. Pharmacologically identical to BPC-157 (compound #81).
Identical to BPC-157 (compound #81). Research suggests growth factor upregulation (EGF, VEGF, HGF, FGF2), NO system modulation, FAK-paxillin activation, collagen organization, gastric mucosal cytoprotection. All mechanisms unvalidated in human trials.
No marketing authorization. Evidence base identical to BPC-157. >100 animal studies, predominantly University of Zagreb. Duplicate listing reflects historical nomenclature. No human Phase III trials. No established human dosing.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
BPC-157 has no marketing authorisation from any major regulatory agency. No human Phase III clinical trials have been completed. The preclinical evidence base consists of over 100 animal studies, predominantly conducted at the University of Zagreb. A small pilot study in ulcerative colitis (4 patients) has been reported but was uncontrolled. No established human dosing, safety profile, or efficacy data from rigorous clinical trials exist. Products available through unregulated channels are not subject to pharmaceutical manufacturing standards, and their composition, purity, and sterility cannot be assured. The gap between the extensive animal literature and the near-complete absence of human clinical data is the defining feature of this compound's evidence base.
Palovarotene (Sohonos) is approved for FOP. The Phase III MOVE trial (107 patients — representing approximately 12% of the global FOP population) initially did not meet statistical significance on its pre-specified primary analysis. However, a post-hoc re-analysis with corrected placebo data showed a 54% reduction in new heterotopic ossification volume. The approval pathway was complex given the ultra-rare nature of FOP. Palovarotene is not a peptide. Important safety considerations include premature growth plate closure in growing children, requiring monitoring. FOP has no other approved treatment.
Thymosin beta-4 has no current marketing authorisation. RegeneRx Biopharmaceuticals has conducted Phase II and Phase III trials of RGN-259 for dry eye disease and neurotrophic keratopathy, with mixed results. A Phase I cardiac study (RGN-352) demonstrated acceptable safety but did not advance to Phase II. Animal studies have consistently shown effects on wound healing and tissue repair. The clinical development programme has focused on ophthalmic applications. Thymosin beta-4 should be distinguished from the 7-amino-acid fragment TB-500 (#82), which is a different molecule with no independent clinical trial data.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
